BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 7634381)

  • 1. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
    Houghton PJ; Cheshire PJ; Hallman JC; Gross JL; McRipley RJ; Sun JH; Behrens CH; Dexter DL; Houghton JA
    Cancer Chemother Pharmacol; 1994; 33(4):265-72. PubMed ID: 8281618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
    Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
    Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
    Zamboni WC; Stewart CF; Thompson J; Santana VM; Cheshire PJ; Richmond LB; Luo X; Poquette C; Houghton JA; Houghton PJ
    J Natl Cancer Inst; 1998 Apr; 90(7):505-11. PubMed ID: 9539245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
    Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
    Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
    Keir ST; Hausheer F; Lawless AA; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):83-7. PubMed ID: 11488529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
    Holcombe RF; Kong KM; Wimmer D
    Anticancer Drugs; 2004 Jul; 15(6):569-74. PubMed ID: 15205598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.